Methotrexate-associated primary cutaneous CD30-positive cutaneous T-cell lymphoproliferative disorder: a case illustration and a brief review.
Pathology case of the month. A recurrent vesicle on the plantar aspect of the foot. Primary cutaneous CD30- positive T-cell lymphoproliferative disorder, consistent with lymphomatoid papulosis.
A Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder Arising in a Patient With Multiple Myeloma and Cutaneous Amyloidosis.
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group.
Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7.
CD30-Positive Lymphoproliferative Disorders.
Nikolaenko L, Zain J, Rosen ST, Querfeld C.
Cancer Treat Res. 2019;176:249-268. doi: 10.1007/978-3-319-99716-2_12.
Cutaneous CD30-Positive Lymphoproliferative Disorders.
Kempf W.
Surg Pathol Clin. 2014 Jun;7(2):203-28. doi: 10.1016/j.path.2014.02.001.
Primary cutaneous CD30+ lymphoproliferative disorders with DUSP22 translocation.
Montes-Moreno S.
Pathologie (Heidelb). 2023 Dec;44(Suppl 3):136-139. doi: 10.1007/s00292-023-01258-6. Epub 2023 Nov 27.
Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment.
Kempf W, Kerl K, Mitteldorf C.
Semin Cutan Med Surg. 2018 Mar;37(1):24-29. doi: 10.12788/j.sder.2018.001.
Primary Cutaneous CD30-Positive Lymphoproliferative Disorders-Current Therapeutic Approaches with a Focus on Brentuximab Vedotin.
Stein T, Robak T, Biernat W, Robak E.
J Clin Med. 2024 Jan 31;13(3):823. doi: 10.3390/jcm13030823.
DUSP22-rearranged primary cutaneous CD30-positive T-cell lymphoproliferative disorders and adult T-cell leukemia/lymphoma frequently share the LEF1+/TIA1- immunophenotype.
Chen BJ, Hsieh SM, Hsieh TH, Jhuang JY, Kao YC.
Hum Pathol. 2024 Aug;150:58-66. doi: 10.1016/j.humpath.2024.07.002. Epub 2024 Jul 4.
Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders.
Abdulla FR, Zhang W, Wu X, Honda K, Qin H, Cho H, Querfeld C, Zain J, Rosen ST, Chan WC, Parekh V, Song JY.
JID Innov. 2021 Nov 15;2(1):100068. doi: 10.1016/j.xjidi.2021.100068. eCollection 2022 Jan.
Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder.
Mallet V, Bruneau J, Zuber J, Alanio C, Leclerc-Mercier S, Roque-Afonso AM, Kraft ARM, Couronné L, Roulot D, Wedemeyer H, Albert ML, Hillon P, Laroche L, Pol S, Hermine O.
J Hepatol. 2017 Dec;67(6):1334-1339. doi: 10.1016/j.jhep.2017.08.011. Epub 2017 Aug 30.
CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.
Prieto-Torres L, Rodriguez-Pinilla SM, Onaindia A, Ara M, Requena L, Piris MÁ.
Haematologica. 2019 Feb;104(2):226-235. doi: 10.3324/haematol.2018.197152. Epub 2019 Jan 10.
